- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancernejm.org
- Breast cancer drug set to transform prostate cancer treatmentMedical Xpress
- ESMO: AstraZeneca, Merck’s Lynparza boosts prostate cancer survival by 31% over J&J, Pfizer-Astellas rivalsFiercePharma
- Pair of prostate cancer drugs found to extend survival timesThe Times
- View Full Coverage on Google News